NOD2 (Q9HC29) variants and mutations
NOD2 (also known as Q9HC29) is a human protein-coding gene encoding a nucleotide-binding oligomerization domain-containing protein 2 protein. It detects bacterial muramyl dipeptide in the cytosol and activates antimicrobial and inflammatory responses. Common loss-of-function variants strongly increase Crohn-disease susceptibility, whereas distinct gain-of-function variants cause Blau syndrome. This analysis covers 749 NOD2 variants and mutations. Of these, 73% have computational variant effect predictions. Disease context includes Blau syndrome, inflammatory bowel disease 1, and Crohn disease. Example NOD2 variants include M1I, M1T, and M1V.
Variant analysis overview
- Gene: NOD2
- Protein: Q9HC29
- UniProt accession: Q9HC29
- Organism: Homo sapiens
- Variants analyzed: 749
- Variant scope: all variants
- Completed: 2026-08-18
Variant and mutation evidence
- Variant composition: 376 unspecified-consequence records; 1 natural variant; 261 missense variants; 65 synonymous variants; 16 stop-gained variants; 19 frameshift variants; 6 in-frame deletions; 2 splice-region variants; 2 in-frame insertions; 1 substitution
- Prediction scores: 550 variants have prediction scores (73% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: Blau syndrome, inflammatory bowel disease 1, Crohn disease, Yao syndrome, inflammatory bowel disease, Behcet disease, enteritis, asthma, childhood onset asthma, Oral ulcer, small bowel Crohn disease, osteosarcoma.
Protein structure and variant hotspots
- Protein features: 3 domains; 11 binding sites.
- Structural context: 424 variants have structural context.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, Interaction Network Analysis, AlphaFold DB, gnomAD constraint, Open Targets, MaveDB, LitVar.
Notable NOD2 variants
Examples include M1I, M1T, M1V, G2W, G2R, G2E, G2G, E3Q. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1I (p.Met1Ile), rs2150776459, ClinGen CA395864211, ClinVar RCV002261982, MetaLR 0.17, MetaSVM -0.91, Uncertain significance, Autoinflammatory syndrome
- M1T (p.Met1Thr), rs765406921, ClinGen CA8051160, ClinVar RCV002529863, MetaLR 0.14, MetaSVM -1.03, Uncertain significance, Regional enteritis; Blau syndrome
- M1V (p.Met1Val), rs1255636125, ClinGen CA395864207, ClinVar RCV002261975, MetaLR 0.14, MetaSVM -1.05, Uncertain significance, Autoinflammatory syndrome
- G2W (p.Gly2Trp), gnomAD 16-50697247-G-T, MetaLR 0.15, MetaSVM -0.97
- G2R (p.Gly2Arg), rs1210065116, gnomAD 16-50697247-G-A, MetaLR 0.15, MetaSVM -0.97
- G2E (p.Gly2Glu), rs1266310979, gnomAD 16-50697248-G-A, MetaLR 0.16, MetaSVM -0.85
- G2G (p.Gly2Gly), rs753028578, gnomAD 16-50697249-G-A, CADD 2.84
- E3Q (p.Glu3Gln), rs976567823, ClinGen CA281248056, ClinVar RCV002529871, ClinVar RCV003420111, MetaLR 0.15, MetaSVM -0.97, Uncertain significance, Blau syndrome; Regional enteritis; not provided
- E3K (p.Glu3Lys), gnomAD 16-50697250-G-A, MetaLR 0.15, MetaSVM -0.97
- E3* (p.Glu3Ter), gnomAD 16-50697250-G-T, CADD 33.00
- E3G (p.Glu3Gly), gnomAD 16-50697251-A-G, MetaLR 0.13, MetaSVM -1.03
- E3E (p.Glu3Glu), gnomAD 16-50697252-A-G, CADD 1.44
- E4* (p.Glu4Ter), gnomAD 16-50697253-G-T, CADD 25.30
- E4K (p.Glu4Lys), gnomAD 16-50697253-G-A, MetaLR 0.22, MetaSVM -0.84
- E4G (p.Glu4Gly), rs1263590939, gnomAD 16-50697254-A-G, MetaLR 0.24, MetaSVM -0.78
- E4D (p.Glu4Asp), gnomAD 16-50697255-G-T, MetaLR 0.19, MetaSVM -0.88
- E4E (p.Glu4Glu), gnomAD 16-50697255-G-A, CADD 1.35
- E5del (p.Glu5del), gnomAD 16-50699505-CAGG-, CADD 19.90
- G5C (p.Gly5Cys), rs140977130, ClinGen CA395864249, ClinVar RCV002798772, MetaLR 0.13, MetaSVM -0.99, Uncertain significance, Inborn genetic diseases
- G5R (p.Gly5Arg), rs140977130, ClinGen CA8051162, ClinVar RCV002540760, MetaLR 0.13, MetaSVM -0.98, Likely benign, Blau syndrome; Regional enteritis
- G5S (p.Gly5Ser), gnomAD 16-50697256-G-A, MetaLR 0.13, MetaSVM -0.99
- G5A (p.Gly5Ala), gnomAD 16-50697257-G-C, MetaLR 0.13, MetaSVM -0.99
- G5D (p.Gly5Asp), rs1421581723, gnomAD 16-50697257-G-A, MetaLR 0.13, MetaSVM -0.99
- G6C (p.Gly6Cys), gnomAD 16-50697259-G-T, MetaLR 0.21, MetaSVM -0.79
- G6S (p.Gly6Ser), gnomAD 16-50697259-G-A, MetaLR 0.19, MetaSVM -0.89
- G6V (p.Gly6Val), gnomAD 16-50697260-G-T, MetaLR 0.13, MetaSVM -1.01
- G6D (p.Gly6Asp), gnomAD 16-50697260-G-A, MetaLR 0.13, MetaSVM -1.01
- G6G (p.Gly6Gly), gnomAD 16-50697261-T-A, CADD 1.92
- S7A (p.Ser7Ala), rs2509121502, ClinGen CA395864268, ClinVar RCV002728690, Uncertain significance, Inborn genetic diseases
- S7P (p.Ser7Pro), gnomAD 16-50697262-T-C, MetaLR 0.17, MetaSVM -0.91
- S7* (p.Ser7Ter), gnomAD 16-50697263-C-A, CADD 25.40
- S7L (p.Ser7Leu), gnomAD 16-50697263-C-T, MetaLR 0.17, MetaSVM -0.89
- S7S (p.Ser7Ser), gnomAD 16-50697264-A-G, CADD 2.05
- S3del (p.Ser3del), gnomAD 16-50699501-CTCG-, CADD 17.10
- S7W (p.Ser7Trp), rs768775316, gnomAD 16-50699503-C-G, MetaLR 0.31, MetaSVM -0.30
- A8S (p.Ala8Ser), rs764563350, ClinGen CA8051163, ClinVar RCV002552981, MetaLR 0.18, MetaSVM -0.91, Uncertain significance, Blau syndrome; Regional enteritis
- A8P (p.Ala8Pro), rs1213629611, gnomAD 16-50697264-AG-A, CADD 16.20
- A8T (p.Ala8Thr), gnomAD 16-50697265-G-A, MetaLR 0.17, MetaSVM -0.92
- A8D (p.Ala8Asp), gnomAD 16-50697266-C-A, MetaLR 0.14, MetaSVM -1.01
- A8V (p.Ala8Val), rs373796134, gnomAD 16-50697266-C-T, MetaLR 0.11, MetaSVM -0.93
- A8G (p.Ala8Gly), rs373796134, gnomAD 16-50697266-C-G, MetaLR 0.14, MetaSVM -1.02
- A8A (p.Ala8Ala), gnomAD 16-50697267-C-A, CADD 2.15
- A8E (p.Ala8Glu), gnomAD 16-50699521-C-A, MetaLR 0.08, MetaSVM -1.00
- S9F (p.Ser9Phe), rs376966894, ClinGen CA8051165, ClinVar RCV003792243, MetaLR 0.21, MetaSVM -0.80, Uncertain significance, Regional enteritis; Blau syndrome
- S9P (p.Ser9Pro), gnomAD 16-50697268-T-C, MetaLR 0.17, MetaSVM -0.91
- S9T (p.Ser9Thr), gnomAD 16-50697268-T-A, MetaLR 0.15, MetaSVM -0.92
- S9Y (p.Ser9Tyr), gnomAD 16-50697269-C-A, MetaLR 0.21, MetaSVM -0.80
- S9S (p.Ser9Ser), rs1385280748, gnomAD 16-50697270-T-G, CADD 6.08
- S9N (p.Ser9Asn), rs1567380395, gnomAD 16-50699530-G-A, MetaLR 0.10, MetaSVM -0.91
- H10N (p.His10Asn), gnomAD 16-50697271-C-A, MetaLR 0.12, MetaSVM -1.01
- H10Y (p.His10Tyr), gnomAD 16-50697271-C-T, MetaLR 0.13, MetaSVM -1.00
- H10R (p.His10Arg), rs2150776546, gnomAD 16-50697272-A-G, MetaLR 0.11, MetaSVM -1.06
- H10H (p.His10His), rs781482576, gnomAD 16-50697273-C-T, CADD 0.19
- H10Q (p.His10Gln), gnomAD 16-50697273-C-A, MetaLR 0.10, MetaSVM -1.06
- D11N (p.Asp11Asn), rs746379299, ClinGen CA8051167, ClinVar RCV003079301, ClinVar RCV003274208, MetaLR 0.13, MetaSVM -1.00, Uncertain significance, Inborn genetic diseases; Regional enteritis; Blau syndrome
- D11V (p.Asp11Val), rs754538287, ClinGen CA8051168, ClinVar RCV003781351, MetaLR 0.16, MetaSVM -0.93, Uncertain significance, Blau syndrome; Regional enteritis
- D11Y (p.Asp11Tyr), gnomAD 16-50697274-G-T, MetaLR 0.13, MetaSVM -0.99
- D11H (p.Asp11His), rs746379299, gnomAD 16-50697274-G-C, MetaLR 0.13, MetaSVM -1.00
- D11G (p.Asp11Gly), gnomAD 16-50697275-A-G, MetaLR 0.16, MetaSVM -0.93
- D11D (p.Asp11Asp), gnomAD 16-50697276-T-C, CADD 3.08
- D11E (p.Asp11Glu), gnomAD 16-50697276-T-G, MetaLR 0.13, MetaSVM -0.95
- E12Q (p.Glu12Gln), NCI-TCGA TCGA novel, MetaLR 0.08, MetaSVM -1.02, Variant assessed as somatic; moderate impact.
- E12* (p.Glu12Ter), gnomAD 16-50697277-G-T, CADD 26.10
- E12K (p.Glu12Lys), gnomAD 16-50697277-G-A, MetaLR 0.16, MetaSVM -0.93
- E12V (p.Glu12Val), gnomAD 16-50697278-A-T, MetaLR 0.17, MetaSVM -0.91
- E12G (p.Glu12Gly), gnomAD 16-50697278-A-G, MetaLR 0.17, MetaSVM -0.91
- E12E (p.Glu12Glu), rs149939201, gnomAD 16-50697279-G-A, CADD 0.74
- E12D (p.Glu12Asp), gnomAD 16-50697279-G-T, MetaLR 0.12, MetaSVM -1.01
- E13K (p.Glu13Lys), rs2150776587, ClinGen CA395864328, ClinVar RCV002573392, MetaLR 0.14, MetaSVM -0.97, Uncertain significance, Blau syndrome; Regional enteritis
- E13* (p.Glu13Ter), gnomAD 16-50697280-G-T, CADD 33.00
- E13G (p.Glu13Gly), gnomAD 16-50697281-A-G, MetaLR 0.15, MetaSVM -0.97
- E13D (p.Glu13Asp), gnomAD 16-50697282-G-C, MetaLR 0.13, MetaSVM -0.97
- E13E (p.Glu13Glu), gnomAD 16-50697282-G-A, CADD 3.24
- E14del (p.Glu14del), rs1276780175, gnomAD 16-50697276-TGAG-, CADD 3.50
- E14* (p.Glu14Ter), gnomAD 16-50697283-G-T, CADD 32.00
- E14Q (p.Glu14Gln), gnomAD 16-50697283-G-C, MetaLR 0.17, MetaSVM -0.89
- E14K (p.Glu14Lys), rs1244953214, gnomAD 16-50697283-G-A, MetaLR 0.18, MetaSVM -0.91
- E14V (p.Glu14Val), gnomAD 16-50697284-A-T, MetaLR 0.15, MetaSVM -0.96
- E14G (p.Glu14Gly), gnomAD 16-50697284-A-G, MetaLR 0.15, MetaSVM -0.96
- E14A (p.Glu14Ala), gnomAD 16-50697284-A-C, MetaLR 0.15, MetaSVM -0.96
- E14E (p.Glu14Glu), gnomAD 16-50699543-G-A, CADD 4.42
- R15K (p.Arg15Lys), NCI-TCGA TCGA novel, MetaLR 0.13, MetaSVM -0.97, Variant assessed as somatic; moderate impact.
- R15G (p.Arg15Gly), rs1963694151, ClinGen CA395864350, ClinVar RCV001116651, ClinVar RCV001784649, MetaLR 0.14, MetaSVM -0.93, Uncertain significance, Blau syndrome; Inflammatory bowel disease 1
- R15* (p.Arg15Ter), gnomAD 16-50697286-A-T, CADD 26.60
- R15I (p.Arg15Ile), gnomAD 16-50697287-G-T, MetaLR 0.15, MetaSVM -0.95
- R15R (p.Arg15Arg), rs1963694299, gnomAD 16-50697288-A-G, CADD 7.72
- R15M (p.Arg15Met), rs104895487, gnomAD 16-50699527-G-T, MetaLR 0.20, MetaSVM -0.76
- A16P (p.Ala16Pro), gnomAD 16-50697289-G-C, MetaLR 0.17, MetaSVM -0.86
- A16T (p.Ala16Thr), rs1264322073, gnomAD 16-50697289-G-A, MetaLR 0.17, MetaSVM -0.90
- A16S (p.Ala16Ser), gnomAD 16-50697289-G-T, MetaLR 0.17, MetaSVM -0.88
- A16E (p.Ala16Glu), gnomAD 16-50697290-C-A, MetaLR 0.15, MetaSVM -0.87
- A16V (p.Ala16Val), gnomAD 16-50697290-C-T, MetaLR 0.17, MetaSVM -0.91
- A16G (p.Ala16Gly), gnomAD 16-50697290-C-G, MetaLR 0.15, MetaSVM -0.88
- A16A (p.Ala16Ala), gnomAD 16-50697291-A-G, CADD 5.53
- S17C (p.Ser17Cys), gnomAD 16-50697292-A-T, MetaLR 0.17, MetaSVM -0.89
- S17T (p.Ser17Thr), gnomAD 16-50697293-G-C, MetaLR 0.12, MetaSVM -0.98
- S17I (p.Ser17Ile), rs1353867731, gnomAD 16-50697293-G-T, MetaLR 0.15, MetaSVM -0.96
- S17N (p.Ser17Asn), rs1353867731, gnomAD 16-50697293-G-A, MetaLR 0.15, MetaSVM -0.96
- S17S (p.Ser17Ser), rs1206486127, gnomAD 16-50697294-T-C, CADD 2.25
- S17R (p.Ser17Arg), rs1206486127, gnomAD 16-50697294-T-G, MetaLR 0.16, MetaSVM -0.92
- V18I (p.Val18Ile), rs886052043, ClinGen CA10643713, ClinVar RCV000356668, ClinVar RCV001782787, MetaLR 0.15, MetaSVM -0.92, Uncertain significance, Regional enteritis; Blau syndrome; Autoinflammatory syndrome
- V18F (p.Val18Phe), rs886052043, gnomAD 16-50697295-G-T, MetaLR 0.20, MetaSVM -0.82
- V18D (p.Val18Asp), gnomAD 16-50697296-T-A, MetaLR 0.26, MetaSVM -0.72
- V18A (p.Val18Ala), gnomAD 16-50697296-T-C, MetaLR 0.17, MetaSVM -0.83
- V18V (p.Val18Val), gnomAD 16-50697297-C-A, CADD 0.70
- L19F (p.Leu19Phe), rs1286500248, gnomAD 16-50697298-C-T, MetaLR 0.16, MetaSVM -0.99
- L19I (p.Leu19Ile), gnomAD 16-50697298-C-A, MetaLR 0.16, MetaSVM -0.95
- L19L (p.Leu19Leu), gnomAD 16-50697300-C-A, CADD 0.69
- L19M (p.Leu19Met), rs761191478, gnomAD 16-50699535-C-A, MetaLR 0.17, MetaSVM -0.76
- L19V (p.Leu19Val), gnomAD 16-50699544-C-G, MetaLR 0.09, MetaSVM -1.06
- L19Q (p.Leu19Gln), rs757914381, gnomAD 16-50699545-T-A, MetaLR 0.05, MetaSVM -1.01
- L19P (p.Leu19Pro), rs757914381, gnomAD 16-50699545-T-C, MetaLR 0.13, MetaSVM -0.96
- L20I (p.Leu20Ile), gnomAD 16-50697301-C-A, MetaLR 0.18, MetaSVM -0.87
- L20F (p.Leu20Phe), gnomAD 16-50697301-C-T, MetaLR 0.17, MetaSVM -0.83
- L20P (p.Leu20Pro), gnomAD 16-50697302-T-C, MetaLR 0.17, MetaSVM -0.91
- L20L (p.Leu20Leu), rs144993105, gnomAD 16-50697303-C-T, CADD 0.13
- L20W (p.Leu20Trp), gnomAD 16-50699581-TC-T, CADD 24.00
- G21* (p.Gly21Ter), rs771671839, ClinGen CA281248107, ClinVar RCV003809237, CADD 24.70, Uncertain significance
- G21R (p.Gly21Arg), rs771671839, ClinGen CA8051171, ClinVar RCV002538183, MetaLR 0.15, MetaSVM -0.96, Uncertain significance, Blau syndrome; Regional enteritis
- G21T (p.Gly21Thr), gnomAD 16-50697302-TCG-T, CADD 10.90
- G21V (p.Gly21Val), gnomAD 16-50697305-G-T, MetaLR 0.16, MetaSVM -0.92
- G21A (p.Gly21Ala), gnomAD 16-50697305-G-C, MetaLR 0.16, MetaSVM -0.96
- G21E (p.Gly21Glu), gnomAD 16-50697305-G-A, MetaLR 0.17, MetaSVM -0.93
- G21G (p.Gly21Gly), gnomAD 16-50697306-A-T, CADD 4.99
- H22N (p.His22Asn), gnomAD 16-50697307-C-A, MetaLR 0.10, MetaSVM -0.99
- H22Y (p.His22Tyr), gnomAD 16-50697307-C-T, MetaLR 0.11, MetaSVM -1.04
- H22R (p.His22Arg), rs1259603692, gnomAD 16-50697308-A-G, MetaLR 0.12, MetaSVM -1.05
- H22P (p.His22Pro), rs1259603692, gnomAD 16-50697308-A-C, MetaLR 0.12, MetaSVM -1.04
- H22H (p.His22His), gnomAD 16-50697309-T-C, CADD 2.67
- S23F (p.Ser23Phe), rs1963696194, gnomAD 16-50697311-C-T, MetaLR 0.15, MetaSVM -0.91
- S23S (p.Ser23Ser), gnomAD 16-50697312-T-A, CADD 4.99
- P24L (p.Pro24Leu), rs149122717, ClinGen CA8051172, ClinVar RCV002261239, ClinVar RCV002544508, MetaLR 0.12, MetaSVM -1.02, Conflicting interpretations, Autoinflammatory syndrome; Blau syndrome; Regional enteritis
- P24T (p.Pro24Thr), gnomAD 16-50697313-C-A, MetaLR 0.12, MetaSVM -1.05
- P24A (p.Pro24Ala), rs1596819304, gnomAD 16-50697313-C-G, MetaLR 0.10, MetaSVM -0.96
- P24S (p.Pro24Ser), gnomAD 16-50697313-C-T, MetaLR 0.11, MetaSVM -1.03
- P24Q (p.Pro24Gln), gnomAD 16-50697314-C-A, MetaLR 0.13, MetaSVM -1.00
- P24P (p.Pro24Pro), rs947655808, gnomAD 16-50697315-G-A, CADD 7.63
- G25A (p.Gly25Ala), rs567793250, ClinGen CA395865146, ClinVar RCV003798654, MetaLR 0.13, MetaSVM -1.03, Uncertain significance, Regional enteritis; Blau syndrome
- G25D (p.Gly25Asp), rs567793250, NCI-TCGA Cosmic COSV1003, MetaLR 0.16, MetaSVM -1.00, Variant assessed as somatic; moderate impact.
- G25S (p.Gly25Ser), gnomAD 16-50697316-G-A, MetaLR 0.13, MetaSVM -0.99
- G25C (p.Gly25Cys), gnomAD 16-50697316-G-T, MetaLR 0.18, MetaSVM -0.92
- G25V (p.Gly25Val), rs950712918, gnomAD 16-50699569-G-T, MetaLR 0.05, MetaSVM -1.10
- C26G (p.Cys26Gly), gnomAD 16-50699488-G-GAG, CADD 26.40
- C26R (p.Cys26Arg), rs1376485544, gnomAD 16-50699490-T-C, MetaLR 0.12, MetaSVM -1.02
- C26F (p.Cys26Phe), gnomAD 16-50699491-G-T, MetaLR 0.13, MetaSVM -1.01
- C26W (p.Cys26Trp), gnomAD 16-50699492-T-G, MetaLR 0.16, MetaSVM -0.86
- C26S (p.Cys26Ser), gnomAD 16-50699499-T-A, MetaLR 0.16, MetaSVM -0.93
- E27Q (p.Glu27Gln), gnomAD 16-50699492-T-TCA, CADD 28.80
- E27G (p.Glu27Gly), gnomAD 16-50699493-G-GGC, CADD 29.00
- E27E (p.Glu27Glu), gnomAD 16-50699495-A-G, CADD 6.88
- E27* (p.Glu27Ter), rs745597071, gnomAD 16-50699565-G-T, CADD 36.00
- E27D (p.Glu27Asp), gnomAD 16-50699567-A-T, MetaLR 0.10, MetaSVM -1.06
- E27K (p.Glu27Lys), rs780204985, gnomAD 16-50699574-G-A, MetaLR 0.10, MetaSVM -1.07
- M28V (p.Met28Val), rs372321755, ClinGen CA8051196, ClinVar RCV002537440, AlphaMissense 0.14, MetaLR 0.45, Uncertain significance, Blau syndrome; Regional enteritis
- S30N (p.Ser30Asn), rs749222396, gnomAD 16-50699578-G-A, MetaLR 0.05, MetaSVM -1.03
- S30R (p.Ser30Arg), gnomAD 16-50699579-T-G, MetaLR 0.04, MetaSVM -1.04
- S30S (p.Ser30Ser), rs768665692, gnomAD 16-50699579-T-C, CADD 4.69
- Q31E (p.Gln31Glu), gnomAD 16-50699517-C-G, MetaLR 0.06, MetaSVM -1.03
- Q31* (p.Gln31Ter), rs1567380372, gnomAD 16-50699517-C-T, CADD 37.00
- Q31R (p.Gln31Arg), rs1294855545, gnomAD 16-50699524-A-G, MetaLR 0.07, MetaSVM -1.10
- Q31P (p.Gln31Pro), rs750745611, gnomAD 16-50699533-A-C, MetaLR 0.09, MetaSVM -1.06
- Q31H (p.Gln31His), gnomAD 16-50699534-G-C, MetaLR 0.07, MetaSVM -1.05
- Q31Q (p.Gln31Gln), rs1000932898, gnomAD 16-50699534-G-A, CADD 7.60
- E32Q (p.Glu32Gln), gnomAD 16-50699604-G-C, MetaLR 0.06, MetaSVM -1.02
- E32D (p.Glu32Asp), gnomAD 16-50699606-G-C, MetaLR 0.01, MetaSVM -1.02
- F34L (p.Phe34Leu), gnomAD 16-50699516-T-G, MetaLR 0.06, MetaSVM -1.06
- F34S (p.Phe34Ser), gnomAD 16-50699572-T-C, MetaLR 0.09, MetaSVM -1.04
- F34F (p.Phe34Phe), rs769855133, gnomAD 16-50699573-C-T, CADD 2.08
- A36P (p.Ala36Pro), gnomAD 16-50699667-G-C, MetaLR 0.16, MetaSVM -0.88
- A36T (p.Ala36Thr), rs1373206847, gnomAD 16-50699667-G-A, MetaLR 0.14, MetaSVM -0.99
- R38G (p.Arg38Gly), rs748200640, gnomAD 16-50699670-A-G, MetaLR 0.14, MetaSVM -0.92
- R38K (p.Arg38Lys), rs772287143, gnomAD 16-50699671-G-A, MetaLR 0.17, MetaSVM -0.85
- R38R (p.Arg38Arg), gnomAD 16-50699672-G-A, CADD 9.92
- R38C (p.Arg38Cys), rs374128251, gnomAD 16-50699673-C-T, AlphaMissense 0.09, MetaLR 0.10
- R38S (p.Arg38Ser), gnomAD 16-50699673-C-A, MetaLR 0.07, MetaSVM -1.04
- R38H (p.Arg38His), rs983465914, gnomAD 16-50699674-G-A, AlphaMissense 0.07, MetaLR 0.03
- S39S (p.Ser39Ser), rs367895771, gnomAD 16-50699600-C-G, CADD 10.90
- S39P (p.Ser39Pro), rs760962549, gnomAD 16-50699613-T-C, MetaLR 0.09, MetaSVM -1.02
- S39C (p.Ser39Cys), rs146149433, gnomAD 16-50699614-C-G, MetaLR 0.12, MetaSVM -1.00
- Q40* (p.Gln40Ter), rs779970018, gnomAD 16-50699649-C-T, CADD 36.00
Public NOD2 analysis runs
- NOD2 analysis run — NOD2 (749 variants) — completed 2026-08-18